News from pari pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

03 Oct, 2018, 13:00 BST PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)

PARI Pharma GmbH, a company focused on the development and commercialization of advanced aerosol delivery systems based on eFlow Technology,...


07 Dec, 2017, 01:00 GMT Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

PARI Pharma GmbH, a company focused on the development and commercialization of advanced aerosol delivery systems based on eFlow® Technology,...


20 Mar, 2017, 14:28 GMT PARI Pharma development featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) is licensed to Breath Therapeutics

PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for...


07 Jun, 2016, 07:00 BST PARI Pharma's Investigational Closed eFlow Nebulizer System Used in Two Successful Phase 3 Clinical Studies Evaluating Sunovion's SUN-101 (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)

PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow...


07 Apr, 2015, 08:30 BST PARI Pharma's Vantobra Granted Marketing Authorisation in Europe

PARI Pharma's Vantobra®, a new highly concentrated tobramycin nebuliser solution for inhalation delivered by a Tolero® nebuliser, was granted...